H5N1 News and Research

Latest H5N1 News and Research

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

Test shows efficacy of avian antibodies against H5N1 and H1N1 influenza in mice

Scientists have discovered for the first time that antibodies in common eggs laid by hens vaccinated against the H5N1 virus can potentially prevent a possible H5N1 pandemic, raising the possibility that the same principle could be applied to the current H1N1 influenza pandemic.

21 Apr 2010

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

Though the world has made "great strides" in eliminating H5N1 (avian flu) from poultry since the "peak of its outbreak in 2006" in 63 countries, the virus persists in Bangladesh, China, Egypt, Indonesia and Vietnam, VOA News reports (DeCapua, 4/16).

20 Apr 2010

WHO discusses shortcomings of its H1N1 response

Keiji Fukuda, the WHO's top influenza expert, on Monday said the organization did not effectively communicate the uncertainties of the H1N1 (swine flu) virus, which led to confusion worldwide, Reuters reports.

15 Apr 2010

New Supramap web-based application to track and stop disease outbreaks

Pathogens can now be easily tracked in time and space as they evolve, an advance that could revolutionize both public health and inform national security in the fight against infectious diseases. Developed by researchers that include scientists at the American Museum of Natural History, Supramap is a new, powerful, web-based application that maps genetic mutations like those among the different strains of avian influenza onto the globe.

13 Apr 2010

Replikin Counts of H5N1 and H1N1 strains on the rise

The most recent BioRadar analysis of the virus genomes of both H5N1, known for high lethality, and H1N1, known for high infectivity, indicates that the Replikin Counts of both strains are rising. Such Count increases in a specific strain have been invariably associated with clinical outbreaks of that strain.

12 Apr 2010

Sinovac Biotech's fourth-quarter sales increase 194%

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and preliminary twelve-month periods ended December 31, 2009.

6 Apr 2010

Company affiliation is the greatest driver of farm-to-farm disease transmission risk: Study

A new study by researchers at the Johns Hopkins Bloomberg School of Public Health examines the potential influence that the business connections between broiler chicken growers may have on the transmission of avian influenza, H5N1. According to the study, the risk of between-farm transmission is significantly greater among farms within the same company group than it is between farms with different company affiliation.

31 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. Pursuant to the agreements, Parenteral is authorized to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

29 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1

Vical Incorporated announced today that the U.S. Navy, through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., has awarded Vical a contract to conduct a Phase 1 clinical trial of the company's Vaxfectin®-formulated DNA vaccine against A/H1N1 pandemic influenza (swine flu).

22 Mar 2010

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences, Inc. today announced that five presentations on the advantages of pressure cycling technology (PCT) in the preparation, processing, identification, and quantification of proteins were made at last week's annual meeting of US HUPO (Human Proteomics Organization) in Denver, Colorado.

From Thermo Fisher Scientific Inc. 19 Mar 2010

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory Viral Infections being held in Taipei.

15 Mar 2010

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Celltrion, Inc., a South Korean biopharmaceutical company, has developed novel human monoclonal antibodies against influenza virus infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1 and the deadly H5N1 avian influenza virus. Preliminary tests in laboratory animals indicate that the novel human monoclonal antibodies can be used to prevent disease when given either before or after infection.

10 Mar 2010

NanoViricides files Universal Form S-3 Shelf Registration with SEC

NanoViricides, Inc., reports that it has filed a “Universal Form S-3 Shelf Registration” with the Securities and Exchange Commission for the sale from time to time of up to $40 million of its securities. The Company recently became eligible to file a shelf registration to register its securities.

5 Mar 2010

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.

3 Mar 2010

Intercell AG's revenues for full year 2009 increase 10.6%

Today, the biotech-vaccine company Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.

2 Mar 2010

Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza.

2 Mar 2010

McGill University and RI MUHC secure $300,000 CIHR grant to develop VLP vaccines

The Canadian Institutes of Health Research (CIHR) have awarded a $300,000 grant for research focusing on the nature of the immune response induced by the action mechanisms of plant-made Virus-Like Particles (VLP) to Dr. Louis Vezina, Chief Scientific Officer of Medicago and to Dr. Brian Ward and Dr. Ciriaco Piccirillo of the Research Institute of the McGill University Health Centre (RI MUHC) and McGill University.

1 Mar 2010

H5N1 News and Research

Latest H5N1 News and Research

Nanoviricides become registered trademark under USPTO

Test shows efficacy of avian antibodies against H5N1 and H1N1 influenza in mice

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

WHO discusses shortcomings of its H1N1 response

New Supramap web-based application to track and stop disease outbreaks

Replikin Counts of H5N1 and H1N1 strains on the rise

Sinovac Biotech's fourth-quarter sales increase 194%

Company affiliation is the greatest driver of farm-to-farm disease transmission risk: Study

Preclinical study of DAS181 for treatment and prevention of ILI published

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1

Pressure BioSciences announces presentations on advantages of PCT

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Celltrion develops novel human monoclonal antibodies against influenza virus infection

NanoViricides files Universal Form S-3 Shelf Registration with SEC

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Intercell AG's revenues for full year 2009 increase 10.6%

Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial

McGill University and RI MUHC secure $300,000 CIHR grant to develop VLP vaccines

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

H5N1 News and Research

Latest H5N1 News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in